BDBM281326 3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl]phenolformate::US10022376, Example 122

SMILES CCc1cc(O)ccc1-c1cc2[nH]ncc2c(n1)N1CCc2cccc(OC)c2C1

InChI Key InChIKey=CMXPYUOPFJEEGA-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 281326   

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 14.9nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 14.9nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 25.1nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 25.1nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 78.1nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 78.1nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 478nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM281326(3-ethyl-4-[4-(8-methoxy-3,4-dihydroisoquinolin-2(1...)
Affinity DataIC50: 478nMpH: 7.4 T: 2°CAssay Description:Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point half log dilution series was created in DMSO...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/14/2019
Entry Details
US Patent